Tritz, Z. P., Ayasoufi, K., Wolf, D. M., Owens, C. A., Malo, C. S., Himes, B. T., … Johnson, A. J. (2024). Supplementary Figure 1 from Anti-PD-1 and extended half-life-IL-2 synergize for treatment of murine glioblastoma independent of host MHC Class I expression. https://doi.org/10.1158/2326-6066.27026369

Tritz, Zachariah P., Katayoun Ayasoufi, Delaney M. Wolf, Carley A. Owens, Courtney S. Malo, Benjamin T. Himes, Cori E. Fain, et al. “Supplementary Figure 1 from Anti-PD-1 and extended half-life-IL-2 synergize for treatment of murine glioblastoma independent of host MHC Class I expression,” September 16, 2024. https://doi.org/10.1158/2326-6066.27026369.

Tritz ZP, Ayasoufi K, Wolf DM, Owens CA, Malo CS, Himes BT, et al. Supplementary Figure 1 from Anti-PD-1 and extended half-life-IL-2 synergize for treatment of murine glioblastoma independent of host MHC Class I expression. 2024.

Tritz, Zachariah P., et al. Supplementary Figure 1 from Anti-PD-1 and extended half-life-IL-2 synergize for treatment of murine glioblastoma independent of host MHC Class I expression. 16 Sept. 2024. Crossref, doi:10.1158/2326-6066.27026369.

Tritz ZP, Ayasoufi K, Wolf DM, Owens CA, Malo CS, Himes BT, Fain CE, Goddery EN, Yokanovich LT, Jin F, Hansen MJ, Parney IF, Wang C, Moynihan KD, Irvine DJ, Wittrup KD, Diaz Marcano RM, Vile RG, Johnson AJ. Supplementary Figure 1 from Anti-PD-1 and extended half-life-IL-2 synergize for treatment of murine glioblastoma independent of host MHC Class I expression. 2024.